Drug intelligence / Profile preview

VX-973

Development stage: Phase 1
Lead developer: Vertex
Modality: Small Molecules
Administration: Oral

Overview

VX-973 is an investigational small molecule drug developed by Vertex Pharmaceuticals for the treatment of pain. It is administered orally as a suspension and acts as a selective blocker of sodium channel protein type 10 subunit alpha (Nav1.8), which plays a key role in pain signal transmission in peripheral neurons. VX-973 is currently in Phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and pharmacodynamics are being evaluated in healthy adults[1][2][5].

Targets

SCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on VX-973.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VX-973.

Explore the full profile